Cancers of the larynx: Tis, T1, T2 evaluation and management

Carol M. Lewis, Steven B. Chinn, Chris Holsinger, Randal S. Weber

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

In the USA, larynx cancer affects an estimated 1 in 250 people. Current treatment modalities emphasize obtaining a cure while maximizing the preservation of function and the quality of life. For early larynx cancers (Tis, T1, T2), these treatment options include primary radiotherapy, transoral endoscopic resection, and conservation laryngeal surgery. Current literature reports similar rates of local control and survival among these modalities, such that management decisions should incorporate the stage, extent of disease, and the anticipated functional outcomes within the context of patient social and medical factors. This chapter discusses the epidemiology, presentation, evaluation, and management of early larynx cancers, with a focus on treatment options and functional considerations.

Original languageEnglish (US)
Title of host publicationHead and Neck Cancer
Subtitle of host publicationMultimodality Management, Second Edition
PublisherSpringer International Publishing
Pages539-553
Number of pages15
ISBN (Electronic)9783319276014
ISBN (Print)9783319275994
DOIs
StatePublished - Jan 1 2016

Keywords

  • Conservation laryngeal surgery
  • Larynx cancer
  • Radiotherapy
  • Transoral endoscopic resection

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Cancers of the larynx: Tis, T1, T2 evaluation and management'. Together they form a unique fingerprint.

Cite this